Clinical Trial Update: Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab with tremelimumab for metastatic non-transitional cell carcinoma of the urothelial tract shows completed results; details no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Bladder
• Bladder Cancer
• Non-transitional Cell Carcinoma of the Urothelial Tract
• Small Cell of the Bladder
• Squamous Cell Carcinoma of the Bladder

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder | Phase 2 | Status: COMPLETED | Results posted: 2021-12-01